Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides

Established prognostic tools in patients with myelodysplastic syndromes (MDS) were largely derived from untreated patient cohorts. Although azanucleosides are standard therapies for higher-risk (HR)-MDS, the relative prognostic performance of existing prognostic tools among patients with HR-MDS rece...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leukemia
Main Authors: Zeidan, AM, Sekeres, MA, Garcia-Manero, G, Steensma, DP, Zell, K, Barnard, J, Ali, NA, Zimmerman, C, Roboz, G, DeZern, A, Nazha, A, Jabbour, E, Kantarjian, H, Gore, SD, Maciejewski, JP, List, A, Komrokji, R
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4775363/
https://ncbi.nlm.nih.gov/pubmed/26464171
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2015.283
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados